Andrea Sartore‐Bianchi

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Total neoadjuvant therapy followed by non-operative management or surgery in stage II–III rectal cancer (NO-CUT): a multicentre, single-arm, phase 2 trial

  The Lancet Oncology · 2025-11-25 · 12 citations

• Figure S3 from <i>BRCA2</i> Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

  2025-11-24

• Figure S4 from <i>BRCA2</i> Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

  2025-11-24

• Supplementary Table S1 from <i>BRCA2</i> Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

  2025-11-24

• Supplementary Table S2 from <i>BRCA2</i> Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

  2025-11-24

• Figure S1 from <i>BRCA2</i> Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

  2025-11-24

• Supplementary Data from Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity

  2025-11-24

• Supplementary Methods from <i>BRCA2</i> Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

  2025-11-24

• Figure S5 from <i>BRCA2</i> Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

  2025-11-24

• Supplementary Table S3 from <i>BRCA2</i> Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

  2025-11-24

• Figure S7 from <i>BRCA2</i> Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

  2025-11-24

• Figure S6 from <i>BRCA2</i> Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

  2025-11-24

• Figure S8 from <i>BRCA2</i> Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

  2025-11-24

• Figure S2 from <i>BRCA2</i> Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

  2025-11-24

• Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies

  Drugs · 2025-11-17 · 6 citations

• 1194 Synthetic linear DNA vaccines as a rapid and potent platform for personalized cancer immunotherapy

  Regular and Young Investigator Award Abstracts · 2025-11-01

• Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy

  ESMO Open · 2025-10-28 · 2 citations

• Impact of chemotherapy on humoral and cellular immune responses to COVID-19 vaccination in patients with solid tumors

  Frontiers in Immunology · 2025-09-25 · 2 citations

• The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer

  Cancer Discovery · 2025-09-22 · 1 citations

• Patient-Reported Experience Measures (PREMs) in patients with metastatic colorectal cancer undergoing treatment supported by feedback auditing: the EPIC study

  ESMO Gastrointestinal Oncology · 2025-08-26